Introduction and objective:
Wnt-1 signaling pathway protein 1 (WISP-1) and complement-C1q TNF-related protein 1 (CTRP1) are adipokines with possible opposite effects in regulating insulin sensitivity. The study investigated the correlation between circulating WISP-1 and CTRP1 in non-diabetic patients. Correlations between adipokines concentrations and biochemical and anthropometric parameters were also studied.

Material and methods:
The cross-sectional study enrolled 107 adult patients without diabetes. Patients with obesity accounted for 52.3% of the study group. Clinical, anthropometric, and laboratory data, including serum levels of WISP-1 and CTRP1, were obtained.

The moderate positive correlation between serum WISP-1 and CTRP1 concentrations was observed (p<0.000001, r=0.49). The correlation was more substantial in non-obese patients than in the obese group (r=0.66 and r=0.36, respectively; p<0.01). Circulating CTRP1 correlated positively with fasting insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), total cholesterol, HDL cholesterol, and LDL cholesterol (p<0.05). WISP-1 level correlated with total cholesterol and HDL cholesterol concentrations (p<0.05). There was no significant difference in WISP-1 and CTRP1 concentrations between the groups with and without insulin resistance. The concentrations of WISP-1 and CTRP1 were significantly higher in females than in males (p<0.05).

WISP-1 and CTRP1 may represent interrelated factors that antagonistically affect insulin resistance.

This study was financed by a large research grant from statutory funding for young researchers – doctoral students of the Doctoral School of Poznań University of Medical Sciences for 2021 (project number 4718).
Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12.
Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: Past, present and future. Crit Rev Clin Lab Sci. 2015;52(4):180–190.
Campbell JE, Newgard CB. Mechanisms controlling pancreatic islet cell function in insulin secretion. Nat Rev Mol Cell Biol. 2021;22(2):142–158.
Montefusco L, D’Addio F, Loretelli C, et al. Anti-inflammatory effects of diet and caloric restriction in metabolic syndrome. J Endocrinol Invest. 2021;44(11):2407–2415.
Kumari R, Kumar S, Kant R. An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab Syndr. 2019;13(4):2409–2417.
Lee BC, Lee J. Cellular and Molecular Players in Adipose Tissue Inflammation in the Development of Obesity-induced Insulin Resistance. Biochim Biophys Acta. 2014;1842(3):446–462.
Liu L, Shi Z, Ji X, et al. Adipokines, adiposity, and atherosclerosis. Cell Mol Life Sci CMLS. 2022;79(5):272.
Tacke C, Aleksandrova K, Rehfeldt M, et al. Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. J Cell Commun Signal. 2018;12(3):539–548.
Mirr M, Owecki M. An Update to the WISP-1/CCN4 Role in Obesity, Insulin Resistance and Diabetes. Medicina (Mex). 2021;57(2):100.
Murahovschi V, Pivovarova O, Ilkavets I, et al. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes. 2015;64(3):856–866.
Hörbelt T, Tacke C, Markova M, et al. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia. 2018;61(9):2054–2065.
Barchetta I, Cimini FA, Capoccia D, et al. WISP1 Is a Marker of Systemic and Adipose Tissue Inflammation in Dysmetabolic Subjects With or Without Type 2 Diabetes. J Endocr Soc. 2017;1(6):660–670.
Wang AR, Yan XQ, Zhang C, et al. Characterization of Wnt1-inducible Signaling Pathway Protein-1 in Obese Children and Adolescents. Curr Med Sci. 2018;38(5):868–874.
Klimontov VV, Bulumbaeva DM, Fazullina ON, et al. Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes. J Cell Commun Signal. Published online November 28, 2019.
Cheng Y, Du X, Zhang B, Zhang J. Increased Serum WISP1 Levels are Associated with Lower Extremity Atherosclerotic Disease in Patients with Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc. 2022;130(4):248–253.
Jung TW, Kang C, Goh J, et al. WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling. J Cell Physiol. 2018;233(8):6077–6087.
Sahin Ersoy G, Altun Ensari T, Subas S, et al. WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2017;30(8):942–946.
Sahin Ersoy G, Altun Ensari T, Vatansever D, et al. Novel adipokines WISP1 and betatrophin in PCOS: relationship to AMH levels, atherogenic and metabolic profile. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2017;33(2):119–123.
Chang JS, Kim TH, Kong ID. Exercise intervention lowers aberrant serum WISP-1 levels with insulin resistance in breast cancer survivors: a randomized controlled trial. Sci Rep. 2020;10(1):10898.
Yu S, Meng S, Xiang M, Ma H. Phosphoenolpyruvate carboxykinase in cell metabolism: Roles and mechanisms beyond gluconeogenesis. Mol Metab. 2021;53:101257.
Claxton DP, Overway EM, Oeser JK, et al. Biophysical and functional properties of purified glucose-6-phosphatase catalytic subunit 1. J Biol Chem. 2022;298(1):101520.
Shabani P, Emamgholipour S, Doosti M. CTRP1 in Liver Disease. Adv Clin Chem. 2017;79:1–23.
Shabani P, Naeimi Khaledi H, Beigy M, et al. Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance? PloS One. 2015;10(3):e0118650.
Xin Y, Lyu X, Wang C, et al. Elevated circulating levels of CTRP1, a novel adipokine, in diabetic patients. Endocr J. 2014;61(9):841–847.
Pan X, Lu T, Wu F, et al. Circulating complement-C1q TNF-related protein 1 levels are increased in patients with type 2 diabetes and are associated with insulin sensitivity in Chinese subjects. PloS One. 2014;9(5):e94478.
Bai B, Ban B, Liu Z, et al. Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose. PloS One. 2017;12(2):e0172271.
Chalupova L, Zakovska A, Adamcova K. Development of a novel enzyme-linked immunosorbent assay (ELISA) for measurement of serum CTRP1: a pilot study: measurement of serum CTRP1 in healthy donors and patients with metabolic syndrome. Clin Biochem. 2013;46(1–2):73–78.
Xin Y, Zhang D, Fu Y, et al. C1qTNF-related protein 1 improve insulin resistance by reducing phosphorylation of serine 1101 in insulin receptor substrate 1. Endocr J. 2017;64(8):787–796.
Han S, Park JS, Lee S, et al. CTRP1 protects against diet-induced hyperglycemia by enhancing glycolysis and fatty acid oxidation. J Nutr Biochem. 2016;27:43–52.
Ren M, Pan J, Yu X, et al. CTRP1 prevents high fat diet-induced obesity and improves glucose homeostasis in obese and STZ-induced diabetic mice. J Transl Med. 2022;20(1):449.
Rodriguez S, Lei X, Petersen PS, et al. Loss of CTRP1 disrupts glucose and lipid homeostasis. Am J Physiol Endocrinol Metab. 2016;311(4):E678-E697.
da Silva C de C, Zambon MP, Vasques ACJ, et al. Homeostatic model assessment of adiponectin (HOMA-Adiponectin) as a surrogate measure of insulin resistance in adolescents: Comparison with the hyperglycaemic clamp and homeostatic model assessment of insulin resistance. PloS One. 2019;14(3):e0214081.
Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13:47.
Brundert M, Heeren J, Merkel M, et al. Scavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells. J Lipid Res. 2011;52(4):745–758.
Chen BH, Song Y, Ding EL, et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care. 2009;32(2):329–334.
Körner A, Neef M, Friebe D, et al. Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int J Obes 2005. 2011;35(4):578–586.
Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 2002;51(9):2734–2741.
Anusha K, Hettiaratchi UPK, Athiththan LV, et al. Inter-relationship of serum leptin levels with selected anthropometric parameters among a non-diabetic population: a cross-sectional study. Eat Weight Disord EWD. 2019;24(3):551–556.
Mirr M, Braszak-Cymerman A, Ludziejewska A, et al. Serum Asprosin Correlates with Indirect Insulin Resistance Indices. Biomedicines. 2023;11(6):1568.
Varghese M, Griffin C, Singer K. The Role of Sex and Sex Hormones in Regulating Obesity-Induced Inflammation. Adv Exp Med Biol. 2017;1043:65–86.
Wolf RM, Jaffe AE, Rodriguez S, et al. Altered adipokines in obese adolescents: a cross-sectional and longitudinal analysis across the spectrum of glycemia. Am J Physiol Endocrinol Metab. 2021;320(6):E1044-E1052.
Han S, Kim JD, Lee S, et al. Circulating CTRP1 Levels in Type 2 Diabetes and Their Association with FGF21. Int J Endocrinol. 2016;2016:5479627.